For help on how to get the results you want, see our search tips.
10 results
Medicine type
Exceptional circumstances Remove Exceptional circumstances filter
Accelerated assessment Remove Accelerated assessment filter
Generic Remove Generic filter
Medicine
Summaries of opinion Remove Summaries of opinion filter
Direct healthcare professional communication Remove Direct healthcare professional communication filter
Categories
Human Remove Human filter
-
List item
Summary of opinion: Rivaroxaban Mylan
rivaroxaban, opinion date: 16/09/2021, Positive, Last updated: 17/09/2021 -
List item
Summary of opinion: Sitagliptin SUN
sitagliptin fumarate, opinion date: 14/10/2021, Positive, Last updated: 15/10/2021 -
List item
Summary of opinion: Lenvima
lenvatinib, opinion date: 14/10/2021, Positive, Last updated: 15/10/2021 -
List item
Summary of opinion: Kisplyx
lenvatinib, opinion date: 14/10/2021, Positive, Last updated: 15/10/2021 -
List item
Summary of opinion: Epclusa (new)
sofosbuvir, velpatasvir, opinion date: 11/11/2021, Positive, Last updated: 12/11/2021 -
List item
Summary of opinion: Kalydeco (new)
ivacaftor, opinion date: 11/11/2021, Positive, Last updated: 12/11/2021 -
List item
Direct healthcare professional communication (DHPC): Lojuxta (lomitapide): Reminder to monitor the liver function of patients treated with Lojuxta and to avoid use in pregnancy
Active substance: Lomitapide, DHPC type: Post-authorisation measure, Last updated: 17/02/2021 -
List item
Direct healthcare professional communication (DHPC): Myalepta (metreleptin): inconsistencies in the package leaflet
Active substance: Metreleptin, DHPC type: Quality defect, Last updated: 18/06/2020 -
List item
Direct healthcare professional communication (DHPC): 5-Fluorouracil (i.v.), capecitabine and tegafur containing products: Pre-treatment testing to identify DPD-deficient patients at increased risk of severe toxicity
Active substance: Fluorouracil, capecitabine, tegafur, DHPC type: Referral - Article 31, Last updated: 04/06/2020 -
List item
Direct healthcare professional communication (DHPC): Cabazitaxel Accord 20 mg/mL concentrate for solution for infusion: Risk of medication errors and mix-up with Jevtana (60 mg/1.5 mL) concentrate and solvent for solution for infusion
Active substance: cabazitaxel, DHPC type: Medication error, Last updated: 28/10/2020